Solid Biosciences Announces Duchenne Muscular Dystrophy Added to Newborn Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Solid Biosciences shared that the U.S. Department of Health and Human Services officially added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, or RUSP, the list of conditions recommended for universal newborn screening across the United States. Adding Duchenne to the RUSP is expected to accelerate detection efforts, leading to earlier access to specialists and supportive intervention and treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLDB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLDB
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.88 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.600
Low
9.00
Averages
14.88
High
20.00
Current: 6.600
Low
9.00
Averages
14.88
High
20.00
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sarepta Shares Rise as 3-Year Elevidys Study Results Offer Promise.
- Positive Study Results: Sarepta Therapeutics announced positive top-line results for its study on Elevidys, a treatment for Duchenne muscular dystrophy.
- Stock Market Reaction: Following the announcement, Sarepta's stock experienced a significant increase.
Continue Reading
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial
- Trial Enrollment Completed: Solid Biosciences announced full enrollment in its Phase 1/2 study for SGT-003 targeting Duchenne muscular dystrophy, with an expected 50-60 patients, indicating significant progress in the gene therapy sector.
- Patient Safety Update: As of January 9, 2025, 33 patients have received SGT-003, showing general tolerability, which enhances confidence in its safety profile, following a previous update on 23 patients' positive responses.
- FDA Interaction Progress: The company expects to provide updates on the Phase 3 confirmatory trial design for SGT-003 by mid-2026, which will offer crucial guidance for future clinical development and may expedite the drug's market entry.
- Positive Market Reaction: Following the enrollment announcement, Solid Biosciences' stock rose on Wednesday, reflecting investor optimism regarding the company's prospects in treating muscle-wasting disorders, potentially driving future funding and partnership opportunities.
Continue Reading